Post-merger, gene therapy player Adverum makes Amber Salzman CEO, delays a clinical trial start
Avalanche Biotechnologies’ acquisition of Paris-based Annapurna and their merger into a new gene therapy company called Adverum Biotechnologies $ADVM is still playing out.
Five months after the two biotechs announced the deal, former Annapurna CEO Amber Salzman is stepping up to the CEO’s job, and one of her first acts as chief is delaying the start of a key trial by a year. Paul Cleveland, meanwhile, is stepping up to the executive chairman’s post in the quick rearrangement of titles.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.